Inhibikase Therapeutics (IKT) Operating Income (QoQ) (2020 - 2026)

Inhibikase Therapeutics (IKT) Operating Income (QoQ) (2020 - 2026) Analysis & Trends

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr)
1 Oculis Holding AG 68,785.72 Bn 68,785.72 Bn -
2 Nanobiotix 1,895.57 Bn 1,895.51 Bn -
3 BeOne Medicines 471.35 Bn 466.56 Bn 1.35 Bn
4 NuCana 279.75 Bn 279.75 Bn -
5 Vertex Pharmaceuticals 120.24 Bn 113.00 Bn 2.59 Bn
6 Regeneron Pharmaceuticals 67.80 Bn 59.04 Bn 3.31 Bn
7 Belite Bio 62.51 Bn 62.51 Bn -
8 Argenx Se 57.38 Bn 57.38 Bn 1.41 Bn
9 Revolution Medicines 37.78 Bn 37.78 Bn -
10 Inhibikase Therapeutics 55.25 Mn -115.12 Mn -

Historic Data

Download Data
DateValue
Mar 31, 2026 -29.52%
Dec 31, 2025 -7.89%
Sep 30, 2025 -17.87%
Jun 30, 2025 25.80%
Mar 31, 2025 -12.91%
Dec 31, 2024 -121.86%
Sep 30, 2024 -15.38%
Jun 30, 2024 -5.61%
Mar 31, 2024 -8.60%
Dec 31, 2023 7.66%
Sep 30, 2023 23.11%
Jun 30, 2023 -31.55%
Mar 31, 2023 -8.77%
Dec 31, 2022 3.95%
Sep 30, 2022 2.73%
Jun 30, 2022 0.01%
Mar 31, 2022 7.95%
Dec 31, 2021 -12.76%
Sep 30, 2021 -70.11%
Jun 30, 2021 -0.12%